The Health and Safety Executive (HSE) has issued a reminder to stakeholders in the biocidal products industry about the upcoming deadlines for the submission of active substance dossiers and renewal applications under the Great Britain Biocidal Products Regulation (GB BPR). These submissions are crucial for maintaining the marketability and use of certain biocidal products within Great Britain.
Dossier Submission Deadline for Chrysanthemum Cinerariaefolium
The HSE has announced a significant deadline for the submission of a full active substance dossier for Chrysanthemum cinerariaefolium, specifically the extract from open and mature flowers of Tanacetum cinerariifolium obtained with hydrocarbon solvents. This substance, redefined from its previous categorizations, is used in product types 18 and 19. The deadline for submission is set for 23 May 2025.
Only entities that have successfully notified their intent to support this active substance/product type combination can submit a dossier. Stakeholders interested in these specific combinations are urged to contact the notifier to potentially collaborate on the submission process.
Failure to submit a dossier by the given deadline will lead to a non-approval decision for the use of this active substance in biocidal products of the relevant types in Great Britain. This would also extend to articles treated with such products, restricting their placement on the GB market.
Active Substance Renewal Deadline
Additionally, the HSE has highlighted the upcoming deadline for the renewal of active substance approvals. This is a part of the regulatory framework ensuring that biocidal products meet current safety and efficacy standards. The specific focus is on Bacillus thuringiensis subsp. kurstaki, strain ABTS-351 in product type 18, with the renewal application deadline set for 27 August 2025.
The GB BPR mandates that renewal applications must be submitted at least 550 days before the expiry of the current approval. This timeline is crucial for any person, company, or consortium wishing to support the continued use of an active substance in the GB market.
Stakeholders are encouraged to review the GB Article 95 List to identify original supporters of the active substances and consider reaching out to collaborate on renewal applications.
The expiration of approval for any active substance/product type combination without a timely renewal application will lead to the cessation of its use in relevant biocidal products in Great Britain, alongside restrictions on the marketability of treated articles.
